Answers are grounded in this paper and cite their sources.
Multi-center retrospective study identifies risk factors for recurrence in clear cell renal cell carcinoma, suggesting immunotherapy benefits.
e16539 Background: Approximately 30% of patients with clear cell renal cell carcinoma experience recurrence after surgery, making it crucial to improve the prognosis for these patients. Stratification of patients with non-metastatic clear cell renal cell carcinoma (ccRCC) based on the risk of postoperative recurrence helps guide adjuvant immunotherapy after surgery. Methods: We enrolled 2,154 patients from two centers. Only patients without postoperative adjuvant therapy were used to analyze risk factors and constructing models. A multivariable model was constructed to predict disease-free survival (DFS) and stratify patients. The log-rank test was used to examine the effects of immune checkpoint inhibitors (ICIs) and targeted therapy on DFS across different strata. Results: We identified seven independent risk factors including: sex, microvascular invasion (MVI), T stage, pathological grade, sarcomatoid differentiation, necrosis and capsular involvement. Using these seven characteristics, a prognostic model (MISNCST model) for non-metastatic clear cell renal cell carcinoma was constructed. Using the constructed model, we stratified the patients and validated the stratification efficacy with DFS, overall survival (OS), and cancer-specific survival (CSS) as endpoints (all p < 0.001). With our model, we stratified patients who either received or did not receive postoperative adjuvant therapy and found that ICIs significantly improved DFS in the high-risk group patients. Compared to the current medication criteria in clinical trials for ICIs, our model demonstrated superior overall performance. Conclusions: We identified 7 crucial prognostic features influencing the prognosis of non-metastatic ccRCC, and developed a prognostic model using these features. Based on our model, we stratified patients and discovered that high-risk patients could benefit from treatment with ICIs. Comparison of stratification approaches between the MISNCST model and other cohorts in terms of the five-year recurrence risk. Training Set (N=1605) Sensitivity Specificity Youden's Index MISNCST model 0.550 0.944 0.494 KEYNOTE-564 0.275 0.972 0.247 PROSPER RCC 0.438 0.932 0.370 CheckMate 914 0.388 0.951 0.339 IMmotion010 0.250 0.984 0.234
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: